X
ADPT icon

Xponance’s Adaptive Biotechnologies ADPT Stock Holding History

Xponance’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
17,579
+1,007
+6% +$15.4K ﹤0.01% 1266
2026
Q1 		$230K Buy
16,572
+1,753
+12% +$27.9K ﹤0.01% 1408
2025
Q4 		$241K Sell
14,819
-277
-2% -$4.52K ﹤0.01% 1295
2025
Q3 		$226K Buy
15,096
+3,419
+29% +$41.7K ﹤0.01% 1300
2025
Q2 		$136K Buy
+11,677
New +$106K ﹤0.01% 1378
2022
Q2 		– Sell
-11,412
Closed -$158K – 1192
2022
Q1 		$158K Buy
11,412
+518
+5% +$8.14K ﹤0.01% 1122
2021
Q4 		$306K Sell
10,894
-122
-1% -$3.74K ﹤0.01% 1035
2021
Q3 		$374K Sell
11,016
-177
-2% -$6.4K 0.01% 992
2021
Q2 		$457K Buy
11,193
+3,025
+37% +$118K 0.01% 963
2021
Q1 		$329K Buy
8,168
+390
+5% +$21.1K 0.01% 934
2020
Q4 		$460K Sell
7,778
-193
-2% -$9.95K 0.01% 784
2020
Q3 		$388K Buy
7,971
+497
+7% +$20.9K 0.01% 760
2020
Q2 		$362K Buy
+7,474
New +$273K 0.01% 753

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Xponance's ADPT Position: Q2 2026 in Review

Xponance increased its Adaptive Biotechnologies (ADPT) stake by 6.1% in Q2 2026, buying an estimated $15.4K and bringing the position to 17,579 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Xponance first reported a position in ADPT in Q2 2020 and has held it in 13 quarters since. The position peaked at $460K in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Xponance held 17,579 shares of Adaptive Biotechnologies worth $377K as of Q2 2026.
  • Xponance bought 1,007 Adaptive Biotechnologies shares in Q2 2026, an estimated $15.4K.
  • Adaptive Biotechnologies made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1266 holding.
  • Xponance first reported a position in Adaptive Biotechnologies in Q2 2020 and has held it in 13 quarters since.
  • Xponance's Adaptive Biotechnologies position peaked at $460K in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.